Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 11/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | C1R | P00736 | 4/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3453025 | 0.95 | ELANE (0.60) | ELANEKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3452980 | 0.86 | ELANE (0.66) | ELANEKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3452727 | 0.86 | C1R (0.51) | ELANEKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3453091 | 0.84 | ELANE (0.67) | ELANEKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3452923 | 0.82 | KDM4E (0.61) | ELANEKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3451689 | 0.81 | ELANE (0.46) | ELANEKDM4ENPC1RAB9ALMNA | |
| SCHEMBL3454073 | 0.81 | ELANE (0.68) | ELANE | |
| SCHEMBL3453634 | 0.77 | ELANE (0.71) | ELANEKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3452604 | 0.75 | ELANE (1.00) | ELANEKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3452308 | 0.74 | NPC1 (0.75) | ELANEKDM4ENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776853-B2 | 2-amino-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2010-08-17 | — | — | US | claimed |
| EP-1144395-B1 | 2-AMINO-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | ALIZYME THERAPEUTICS LTD (GB) | 2005-04-20 | — | — | EP | claimed |
| US-6656934-B2 | Enzyme inhibitor | ALIZYME THERAPEUTICS LIMITED (GB) | 2003-12-02 | — | — | US | claimed |
| US-20030191123-A1 | 2-amino-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2003-10-09 | — | — | US | claimed |
| US-20030013707-A1 | 2-amino-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2003-01-16 | — | — | US | claimed |
| US-7776853-B2 | 2-amino-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2010-08-17 | — | — | US | disclosed |
| US-7776853-B2 | 2-amino-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2010-08-17 | — | — | US | disclosed |
| US-7776853-B2 | 2-amino-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2010-08-17 | — | — | US | disclosed |
| US-6656934-B2 | Enzyme inhibitor | ALIZYME THERAPEUTICS LIMITED (GB) | 2003-12-02 | — | — | US | disclosed |
| US-20030191123-A1 | 2-amino-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2003-10-09 | — | — | US | disclosed |
| US-20030013707-A1 | 2-amino-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2003-01-16 | — | — | US | disclosed |
| EP-1143977-A1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | Alizyme Therapeutics Limited (GB) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000040247-A1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | ALIZYME THERAPEUTICS LIMITED (GB) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191123-A1 | 2-amino-benzoxazinone derivatives for the treatment of obesity | CYP4X1, CYP2B6, BBOX1 | ELANE 730/4885KDM4E 556/4885NPC1 2324/4885 |
| US-20030013707-A1 | 2-amino-benzoxazinone derivatives for the treatment of obesity | CYP4X1, CYP2B6, BBOX1 | ELANE 730/4885KDM4E 556/4885NPC1 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.